Novo Nordisk's Oral Weight-Management Tablet Application Accepted in China
Novo Nordisk's marketing application for its oral semaglutide tablet, marketed as NovoFine, for long-term weight management has been formally accepted by China's National Medical Products Administration. The application, submitted on August 27, 2026, is now under review. If approved, it would become one of the first oral GLP-1 drugs for weight management in the Chinese market.
According to the official website of the Center for Drug Evaluation (CDE) under China's National Medical Products Administration, Novo Nordisk's marketing application for its oral semaglutide tablet, marketed as NovoFine, for long-term weight management has been formally accepted. The application was submitted on August 27, 2026, and is currently in the review process.
NovoFine is the oral formulation of semaglutide, and this application targets the indication of long-term weight management. If approved, the product would become one of the oral GLP-1 drugs available for weight management in the Chinese market. The progress of the review and the final approval decision will be announced by the CDE in accordance with its procedures.
Why this event matters
The event has a measured impact on 2 industrys. The strongest current signal is positive for Pharmaceuticals, with intensity 70/100 and 80% confidence over a medium term horizon.
Pharmaceuticals
- Direction
- positive
- Intensity
- 70
- Confidence
- 80%
- Horizon
- Medium term
Biotechnology
- Direction
- positive
- Intensity
- 60
- Confidence
- 70%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.